KPRX

Kiora Pharmaceuticals Inc. Common Stock (KPRX)

Stock · NASDAQ · Health Care

$2.4as of 10/16/2026

Price chart

Open in TradingView

Active signals

200 SMA Touch97.0%Support Reject69.2%
Resistance level
$2.5
Industry
Biotechnology: Pharmaceutical Preparations

KPRX Signal Track Record

How signals performed across all stocks →

What KPRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike37-2.4%38%
Bollinger Band Breakout23-10.6%13%
Bollinger Band Breakdown21+1.8%57%
200-Day Moving Average TouchActive now8-12.1%13%
Any 20-session window (baseline)-2.8%41%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About KPRX

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
13

Fundamentals

1-day range
$2.35$2.46
Market cap
$11.35M
P/E (trailing)
—
P/E (forward)
-1.08
EPS (trailing)
$-2.47
Dividend yield
—
Beta
-0.19
Avg. volume
15.6K
Dividend pay date
August 30, 2019
52-week range
$1.76$2.91

How Kiora Pharmaceuticals Inc. Common Stock Makes Money

Where the revenue actually goes — FY2024 annual results

market-wall.comTotalRevenue$16.02MNet Income$3.59M (22%)R&D$7.84M (49%)SG&A$5.54M (35%)Tax$2.07M (13%)KPRX

Source: 10-K filed Mar 25, 2025 · via SEC EDGAR / Finnhub

Operating Income$4.51M(28%)

Forecasts

1 analyst ratings

Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$12
+400.0%
Median
$12
+400.0%
Low
$12
+400.0%

Kiora Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • KPRX
    Kiora Pharmaceuticals Inc. Common Stock
    $2.4
    ▼ 0.41%
    Market cap $11.35MP/E —
    $1.76$2.91
  • LNAI
    Lunai Bioworks Inc. Common Stock
    $0.68
    ▼ 17.68%
    Market cap $10.97MP/E —
    $0.8757$13.28
  • BFRG
    Bullfrog AI Holdings Inc. Common Stock
    $0.513
    ▼ 4.11%
    Market cap $10.96MP/E —
    $0.4251$1.96
  • BLRX
    BioLineRx Ltd. American Depositary Shares
    $2.01
    ▼ 1.95%
    Market cap $12.14MP/E Infinity
    $1.1$2.3
  • PHIO
    Phio Pharmaceuticals Corp. Common Stock
    $0.871
    ▼ 5.94%
    Market cap $12.31MP/E —
    $0.8127$4.19
  • TOVX
    Theriva Biologics Inc. Common Stock
    $0.21
    ▲ 0.00%
    Market cap $10.32MP/E —
    $0.1628$0.8632
  • ADIL
    Adial Pharmaceuticals Inc Common Stock
    $3.49
    ▲ 11.15%
    Market cap $10.29MP/E —
    $1.31$232.5

P/E shows — for peers not currently carrying a live signal of their own.

Insider Activity

Insider Actions →
Acquired
220.0K
Disposed
2.8K

Institutional Ownership

March 31, 2026

Total shares held
326.0K
Total value held
$629.1K
Institutional holders
15
Top holders this quarter
  • Unknown167.9K
  • Unknown49.5K
  • Unknown47.9K
  • Unknown19.9K
  • Unknown14.7K
  • Unknown12.0K
  • Unknown10.0K
  • Unknown1.4K
  • Unknown1.3K
  • Unknown995

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.